KalVista Pharmaceuticals, Inc. $KALV Shares Acquired by Blue Owl Capital Holdings LP

Blue Owl Capital Holdings LP grew its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 188.0% in the fourth quarter, HoldingsChannel reports. The fund owned 360,000 shares of the specialty pharmaceutical company’s stock after acquiring an additional 235,000 shares during the quarter. KalVista Pharmaceuticals accounts for about 0.4% of Blue Owl Capital Holdings LP’s portfolio, making the stock its 17th largest position. Blue Owl Capital Holdings LP’s holdings in KalVista Pharmaceuticals were worth $5,814,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Vanguard Group Inc. raised its position in shares of KalVista Pharmaceuticals by 3.7% in the third quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock worth $30,464,000 after acquiring an additional 88,720 shares during the period. Tudor Investment Corp ET AL acquired a new position in shares of KalVista Pharmaceuticals in the third quarter worth about $24,360,000. Parkman Healthcare Partners LLC raised its position in shares of KalVista Pharmaceuticals by 155.5% in the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock worth $21,132,000 after acquiring an additional 1,055,940 shares during the period. Schroder Investment Management Group raised its position in shares of KalVista Pharmaceuticals by 108.7% in the third quarter. Schroder Investment Management Group now owns 1,158,457 shares of the specialty pharmaceutical company’s stock worth $14,145,000 after acquiring an additional 603,499 shares during the period. Finally, Ameriprise Financial Inc. raised its position in shares of KalVista Pharmaceuticals by 2,258.6% in the second quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock worth $10,685,000 after acquiring an additional 905,053 shares during the period.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on KALV shares. Leerink Partners downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Stifel Nicolaus upped their price objective on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. JonesTrading downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Citizens Jmp downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Three equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, KalVista Pharmaceuticals has an average rating of “Hold” and a consensus price target of $30.60.

KalVista Pharmaceuticals Price Performance

KALV opened at $26.79 on Monday. KalVista Pharmaceuticals, Inc. has a twelve month low of $9.83 and a twelve month high of $26.85. The company has a quick ratio of 5.10, a current ratio of 5.17 and a debt-to-equity ratio of 8.18. The company has a 50-day moving average price of $21.35 and a 200 day moving average price of $17.31. The company has a market cap of $1.43 billion, a PE ratio of -7.74 and a beta of -0.12.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The company had revenue of $39.17 million for the quarter, compared to analysts’ expectations of $39.03 million. Sell-side analysts expect that KalVista Pharmaceuticals, Inc. will post -0.96 earnings per share for the current fiscal year.

Insider Activity

In related news, major shareholder Venrock Healthcare Capital Par sold 174,645 shares of the company’s stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $16.95, for a total transaction of $2,960,232.75. Following the completion of the transaction, the insider owned 5,129,340 shares in the company, valued at $86,942,313. This represents a 3.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Brian Piekos sold 1,862 shares of the company’s stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $20.22, for a total transaction of $37,649.64. Following the sale, the chief financial officer directly owned 18,150 shares of the company’s stock, valued at approximately $366,993. This represents a 9.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 240,606 shares of company stock worth $4,210,242. Company insiders own 4.30% of the company’s stock.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.